Literature DB >> 2441913

Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes.

M Barral-Netto, S G Reed, M Sadigursky, G Sonnenfeld.   

Abstract

Successful immunization of highly susceptible BALB/c mice against progressive infection by Leishmania mexicana amazonensis, using whole solubilized promastigotes was achieved. The best immunization schedule consisted of three weekly injections of 5 X 10(7) parasite equivalents. Intravenous was superior to intraperitoneal or subcutaneous immunization. Protection persisted for up to 2 months after immunization, and beneficial effects could be observed in long-term follow-up (24 weeks after infection). Immunized mice exhibited marked reduction in primary lesion size, as well as reduction of the number of parasites in the spleen, and developed less metastases. High titres of specific anti-L. m. amazonensis IgG antibodies resulted from immunization, but titres did not correlate with protection. Groups with widely differing pre-infection antibody titres were equally protected, and similar antibody titres resulted in different levels of protection. Immunization alone did not induce significant serum interferon-gamma levels and specific delayed-type hypersensitivity (DTH) reactions, but resulted in the persistence of positive (DTH) reactions after infection, at a time when infected control animals had suppressed responses. Resistance to leishmaniasis appears to depend on cell mediated immune mechanisms, and the possibility of immunization with a solubilized antigen without adjuvant is intriguing and opens new perspectives in this area.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441913      PMCID: PMC1542545     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Is the delayed-type hypersensitivity observed after a low dose of antigen mediated by helper T cells?

Authors:  G Milon; G Marchal; M Seman; P Truffa-Bachi; V Zilberfarb
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

2.  Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility.

Authors:  G F Mitchell; E Handman
Journal:  Aust J Exp Biol Med Sci       Date:  1983-02

3.  Single gene control of resistance to cutaneous leishmaniasis in mice.

Authors:  L J DeTolla; P A Scott; J P Farrell
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

4.  Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection.

Authors:  J G Howard; S Nicklin; C Hale; F Y Liew
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

6.  Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes.

Authors:  J G Howard; F Y Liew; C Hale; S Nicklin
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

7.  Mechanism of lethal effect of human serum upon Leishmania donovani.

Authors:  R D Pearson; R T Steigbigel
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

8.  Resistance to cutaneous leishmaniasis in genetically susceptible BALB/c mice.

Authors:  G F Mitchell; J M Curtis; E Handman
Journal:  Aust J Exp Biol Med Sci       Date:  1981-10

9.  Late metastatic Leishmaniasis in the mouse. A model for mucocutaneous disease.

Authors:  A Barral; E A Petersen; D L Sacks; F A Neva
Journal:  Am J Trop Med Hyg       Date:  1983-03       Impact factor: 2.345

10.  Immunological regulation of experimental cutaneous leishmaniasis. 2. Studies with Biozzi high and low responder lines of mice.

Authors:  C Hale; J G Howard
Journal:  Parasite Immunol       Date:  1981       Impact factor: 2.280

View more
  6 in total

1.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

2.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  T-lymphocytes in experimental Leishmania amazonensis infection: comparison between immunized and naive BALB/c mice.

Authors:  M Pompeu; A L Freitas; G A dosReis; M Barral-Netto
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

4.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis.

Authors:  J E Haberer; A M Da-Cruz; L Soong; M P Oliveira-Neto; L Rivas; D McMahon-Pratt; S G Coutinho
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Up-regulation of T helper 2 and down-regulation of T helper 1 cytokines during murine retrovirus-induced immunodeficiency syndrome enhances susceptibility of a resistant mouse strain to Leishmania amazonensis.

Authors:  M Barral-Netto; J S da Silva; A Barral; S Reed
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.